Herceptin (trastuzumab) therapy during pregnancy: Association with reversible anhydramnios

Obstetrics and Gynecology

Volumn 105, Issue 3, 2005, Pages 642-643

  Watson, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ADULT; AMNION FLUID; ANHYDRAMNIOS; ARTICLE; BIOMETRY; BREAST CANCER; CARDIOTOXICITY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDRAMNIOS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INFANT, NEWBORN; OLIGOHYDRAMNIOS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 13944252582     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000141570.31218.2b     Document Type: Article

References (3)

1. Leslie KK. Chemotherapy and pregnancy. Clin Obstet Gynecol 2002;45:153-64.
2. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-600.
3. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuroregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-8.